NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR
ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES
DESCRIBED HEREIN.
Oslo, 6 February 2025
Reference is made to the stock exchange announcement by Oncoinvent ASA
("Oncoinvent" or the "Company") on 22 January 2025 regarding the launch of a
subsequent offering of up to 5,500,000 new shares ("Offer Shares") in the
Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 2
per Offer Share (the "Subsequent Offering"), as well as the stock exchange
announcement from earlier today, regarding today being the last day of the
subscription period in the Subsequent Offering.
The subscription period in the Subsequent Offering expired today, on 6 February
2025 at 12:30 hours (CET). The final results show that the Company has received
valid subscriptions for a total of 11,075,035 Offer Shares. As 5,500,000 Offer
Shares were offered under the Subsequent Offering, the Subsequent Offering was
accordingly oversubscribed.
Notifications of allocated Offer Shares in the Subsequent Offering and the
corresponding amount to be paid by each subscriber will be set out in a separate
allocation notification to each subscriber. The allocation notifications are
expected to be available through the Norwegian Central Securities Depository
tomorrow, on 7 February 2025. The deadline for payment for the Offer Shares is
11 February 2025, in accordance with the payment instructions set out in the
Company's information document that is available at the Managers' (as defined
below) websites: https://www.carnegie.no/ongoing-prospectuses-and-offerings/ and
www.dnb.no/emisjoner.
The Offer Shares may not be transferred or traded until they are fully paid and
the share capital increase pertaining to the Subsequent Offering has been
registered with the Norwegian Register of Business Enterprises (Nw.:
Foretaksregisteret). The Company will by a stock exchange announcement announce
when the share capital increase has been registered.
Subject to timely payment of the Offer Shares subscribed for and allocated in
the Subsequent Offering, the issuance and delivery of the Offer Shares
pertaining to the Subsequent Offering is expected to be completed on or about 18
February 2025. The Managers (as defined below) may be contacted for information
regarding allocation, payment and delivery of the Offer Shares.
Following the issuance of the 5,500,000 Offer Shares, the Company's share
capital will be NOK 9,774,334.30, divided into 97,743,343 shares, each with a
nominal value of NOK 0.10.
Advisors:
Carnegie AS and DNB Markets, a part of DNB Bank ASA are acting as managers in
the Subsequent Offering (the "Managers").
Advokatfirmaet Thommessen AS is acting as legal advisor to the Company.
Advokatfirmaet Wiersholm AS is acting as legal advisor to the Managers.
Further information about the Subsequent Offering is included in the information
document.
The information in this announcement is considered to be inside information
pursuant to the EU Market Abuse Regulation and is subject to the disclosure
requirements pursuant to section 5-12 the Norwegian Securities Trading Act.
This stock exchange announcement was published by Tore Kvam, CFO of the Company
on 6 February 2025 20:05 CET on behalf of the Company.
About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing
innovative treatments for solid cancers. The technology platform is focused on
the use of alpha-emitting radionuclides to deliver powerful radiation directly
to cancer cells. The Company's lead product candidate, Radspherin®, is being
advanced through clinical development by a team with experience from all stages
of radiopharmaceutical development. Internal manufacturing and supply chain
capabilities have been established, which now have the capacity to supply
Radspherin® for multi-center phase 2 clinical studies.
For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com
Important information
The release is not for publication or distribution, in whole or in part directly
or indirectly, in or into Australia, Canada, Japan or the United States
(including its territories and possessions, any state of the United States and
the District of Columbia). This release is an announcement issued pursuant to
legal information obligations. It is issued for information purposes only, and
does not constitute or form part of any offer or solicitation to purchase or
subscribe for securities, in the United States or in any other jurisdiction. The
securities mentioned herein have not been, and will not be, registered under the
United States Securities Act of 1933, as amended (the "US Securities Act"). The
securities may not be offered or sold in the United States except pursuant to an
exemption from the registration requirements of the US Securities Act.
The Company does not intend to register any portion of the offering of the
securities in the United States or to conduct a public offering of the
securities in the United States. Copies of this announcement are not being made
and may not be distributed or sent into Australia, Canada, Japan or the United
States.
This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14
June 2017 on prospectuses to be published when securities are offered to the
public or admitted to trading on a regulated market, and repealing Directive
2003/71/EC (as amended) as implemented in any Member State.
The issue, subscription or purchase of shares in the Company is subject to
specific legal or regulatory restrictions in certain jurisdictions. Neither the
Company nor the Managers assume any responsibility in the event there is a
violation by any person of such restrictions. The distribution of this release
may in certain jurisdictions be restricted by law. Persons into whose possession
this release comes should inform themselves about and observe any such
restrictions. Any failure to comply with these restrictions may constitute a
violation of the securities laws of any such jurisdiction. The Managers are
acting for the Company and no one else in connection with the Subsequent
Offering and will not be responsible to anyone other than the Company providing
the protections afforded to their respective clients or for providing advice in
relation to the Subsequent Offering and/or any other matter referred to in this
release.
Forward-looking statements: This release and any materials distributed in
connection with this release may contain certain forward-looking statements. By
their nature, forward-looking statements involve risk and uncertainty because
they reflect the Company's current expectations and assumptions as to future
events and circumstances that may not prove accurate. A number of material
factors could cause actual results and developments to differ materially from
those expressed or implied by these forward-looking statements.